Atacicept

阿塞西普

Report date: 2025/11/10 15:23:33

Base Information

Drug NameAtacicept
Drug Alias NameTACI-Ig
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionB-cell-activating factor/B lymphocyte stimulator inhibitorsTumor necrosis factor ligand superfamily member 13 inhibitors
TargetsB-cell-activating factor/B lymphocyte stimulatorTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsLupus Erythematosus, SystemicUrinary Bladder DiseasesNephrotic Syndrome +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesZymogenetics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Happy Life Technology Co LtdVera Therapeutics Inc
Inactive CompaniesEmd Serono IncZymogenetics IncEmd Serono Research & Development Institute Inc +[4] 
Active IndicationsUrinary Bladder DiseasesNephrotic SyndromeGlomerulosclerosis, Focal Segmental +[6] 
Inactive IndicationsLupus Erythematosus, SystemicLupus NephritisOptic Neuritis +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG